Citius Pharmaceuticals (CTXR) Price to Earnings (2014 - 2026)

Citius Pharmaceuticals (CTXR) has reported Price to Earnings for 13 consecutive years, with 1.86 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings rose 6.66% year-over-year to 1.86; the trailing twelve-month figure through Jun 2026 stood at 0.36 (up 16.63% YoY), and the FY2025 full-year result was 0.37, up 83.77% from the prior year.
• Price to Earnings retreated to 1.86 in Q2 2026 per CTXR's latest filing, from 0.95 in the prior quarter.
• Across five years, Price to Earnings topped out at 0.95 in Q1 2026 and bottomed at 864.87 in Q1 2022.
• Historically, Price to Earnings has averaged 267.84 across 5 years, with a median of 243.51 in 2023.
• The sharpest annual moves came in 2023 and 2025: Price to Earnings plunged 48.22% in 2023, then soared 99.71% in 2025.
• Over 5 years, Price to Earnings stood at 803.55 in 2022, then surged by 59.45% to 325.81 in 2023, then soared by 99.03% to 3.16 in 2024, then jumped by 32.9% to 2.12 in 2025, then advanced by 12.46% to 1.86 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 1.86, 0.95, and 2.12 for Q2 2026, Q1 2026, and Q4 2025 respectively.